India's Dr Reddy's Bags U.S. Nod For Ibandronate Sodium Tabs
Indian drug manufacturer Dr Reddy's Laboratories has bagged nod from U. S. Food and Drug Administration for marketing ibandronate sodium tabs utilized to cure osteoporosis.
The pills are the generic edition of Boniva, a product sold by a unit of Swiss drug manufacturer Roche.
Cipla, another Indian drug manufacturer, bagged U. S. authoritarian authorization for AIDS treatment medicine nevirapine.
The medicine is a generic edition of Boehringer Ingelheim's Viramune tabs.
The shares of Dr Reddy's hit an intraday peak of Rs 1,770.70 and an intraday low of Rs 1,740.
At 13:10 p. m., the company's scrip was trading at Rs 1,748.55 after declining Rs 12.20 (0.69%).
It was ruling with volumes of 4,915 scrips.
In the preceding trading session, the company scrip ended up 0.04% at Rs 1,760.75.
The company's trailing 12-month (TTM) earnings per share stood at Rs 51.10 per share.
The stock's price-to-earnings proportion remained at 34.22.